Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, open-label, multicenter, phase III clinical study that aims to evaluate the efficacy and safety of Nelarabine injection in the treatment of refractory or recurrent T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) in both children and adults. The trial includes 83 subjects, consisting of 35 adults and 48 children, and aims to evaluate the composite complete response rate (CCR) within 2 cycles, assessed by the Independent Review Committee (IRC), following treatment with Nelarabine injection for children and adults with refractory or recurrent T-ALL and T-LBL. The sample size of this study is estimated according to the treatment period of 4 cycles.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06434467
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Jun Ma, Doctor
Phone 13304518000
Email majun0322@126.com
Status Not yet recruiting
Phase Phase 3
Start date May 2024
Completion date May 2026

See also
  Status Clinical Trial Phase
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT04620655 - RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL N/A
Recruiting NCT04582487 - Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL N/A
Suspended NCT04828174 - Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies Phase 1
Not yet recruiting NCT05068401 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Recruiting NCT03558412 - A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma Phase 4
Recruiting NCT05576532 - Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia Phase 2
Withdrawn NCT04860817 - A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL Early Phase 1
Recruiting NCT04004637 - CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia Phase 1
Recruiting NCT06136364 - CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study Phase 1
Recruiting NCT06376721 - Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Phase 1/Phase 2